Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Paroxysmal Supraventricular Tachycardia
Interventions: Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System; Drug · Device
Lead sponsor: Milestone Pharmaceuticals Inc.; Other
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 22
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Alamitos, California + 18 more

Conditions: Primary Hyperoxaluria
Interventions: Oxalobacter formigenes, Placebo; Biological · Drug
Lead sponsor: OxThera; Industry
Eligibility: 5 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Secondarily Infected Traumatic Skin Lesions
Interventions: Mupirocin Calcium, Vehicle; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 18 Months and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Cardiac Resynchronization Therapy
Interventions: Bi-ventricular lead placement; Device
Lead sponsor: Stereotaxis; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 6
States / cities: Gainesville, Georgia • Lexington, Kentucky • Boston, Massachusetts + 3 more

Conditions: Congenital Sucrase-isomaltase Deficiency (CSID)
Interventions: Not listed
Lead sponsor: QOL Medical, LLC; Industry
Eligibility: Up to 18 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 19
States / cities: Los Angeles, California • Oakland, California • Aurora, Colorado + 16 more

Conditions: Shoulder Instability
Interventions: Not listed
Lead sponsor: Society of Military Orthopedic Surgeons; Network
Eligibility: 17 Years to 38 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 2
States / cities: San Diego, California • Colorado Springs, Colorado

Conditions: Chronic Pain, Brain Injuries, Traumatic, Multiple Sclerosis, Spinal Cord Injuries, Amputation
Interventions: E-TIPS; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions: BQ123, Saline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: LPCN 1144 Formulation A, LPCN 1144 Formulation B, Placebo; Drug
Lead sponsor: Lipocine Inc.; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 19
States / cities: El Cajon, California • Murrieta, California • Rialto, California + 14 more

Conditions: Migraine
Interventions: Lasmiditan, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,633 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Huntsville, Alabama • Phoenix, Arizona • La Jolla, California + 10 more

Conditions: Cardiovascular Disease
Interventions: Olpasiran, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Bridgeport, Connecticut • Jacksonville, Florida • Overland Park, Kansas + 3 more

Conditions: Carcinoma in Situ, Transitional Cell Carcinoma, Non-muscle Invasive Bladder Cancer
Interventions: VALSTAR - Maintenance Therapy, No Maintenance treatment ( Standard of Care); Drug · Other
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Phoenix, Arizona • Denver, Colorado • Cumberland, Maryland + 3 more

Conditions: Papillary Renal Cell Carcinoma
Interventions: savolitinib, durvalumab, sunitinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Cataracts
Interventions: Lens implantation -1.00 D postop target, Lens implantation 0.00 D postop target; Device
Lead sponsor: Calhoun Vision, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 5
States / cities: Los Altos, California • Los Angeles, California • Indianapolis, Indiana + 2 more

Conditions: IgA Nephropathy (IgAN)
Interventions: Avacopan, Prednisone, Methylprednisolone (drug), Prednisolone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Psoriasis
Interventions: Anti IL-12 monoclonal antibody/ABT-874, placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 16
States / cities: San Diego, California • Alpharetta, Georgia • Skokie, Illinois + 13 more

Conditions: Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions: GB001, Placebo; Drug
Lead sponsor: GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 29
States / cities: Tucson, Arizona • Jonesboro, Arkansas • Los Angeles, California + 24 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Interventions: Busulfan, Fludarabine, Total-body irradiation, Cyclophosphamide, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Bone Marrow Hematopoietic Stem Cell Transplantation, Post-transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient-Reported Outcomes; Drug · Radiation · Procedure + 1 more
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 1 Year and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 39
States / cities: Duarte, California • San Francisco, California • Stanford, California + 28 more

Conditions: Brain Injury, Aggression
Interventions: Amantadine Hydrochloride, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 16 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Indianapolis, Indiana • Boston, Massachusetts • Charlotte, North Carolina + 3 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: Abiraterone acetate, Placebo, Hydrocortisone, Fludrocortisone; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 2 Years to 9 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more

Conditions: Secondary Hypogonadism
Interventions: Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 9
States / cities: Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more

Conditions: Breast Cancer
Interventions: MRI, Lumbar puncture; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Plasma Cell Myeloma
Interventions: Isatuximab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 10
States / cities: Scottsdale, Arizona • San Francisco, California • Detroit, Michigan + 7 more

Conditions: Atrial Fibrillation
Interventions: Ablation; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: South Bend, Indiana • Boston, Massachusetts

Search by objective public record fields.

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions

MAGNET CRT Feasibility - Efficiency of LV Lead Placement Comparing Conventional vs. Magnetic Guidance

Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Prevalence Study (GPS)

Circumferential Lesions of the Glenoid Labrum

Telehealth Pain Self-Management for Employed Adults

The Role of Endothelin in the Supine Hypertension of Autonomic Failure

The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Safety and Effectiveness of the Calhoun Vision Light Adjustable Intraocular Lens (LAL)

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

GB001 in Adult Participants With Chronic Rhinosinusitis

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study

Androgen Reduction in Congenital Adrenal Hyperplasia

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

Low Fluoroscopy Afib Ablation Registry